Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
111.52 USD | -0.49% |
|
+1.00% | +16.23% |
Jan. 24 | HealthEquity, Inc. : Save on your health care expenses | ![]() |
Jan. 15 | HealthEquity, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 08:15 AM |
Fiscal Period: January | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 532M | 734M | 757M | 862M | 1B | |||||
Other Revenues, Total | - | - | - | - | - | |||||
Total Revenues | 532M | 734M | 757M | 862M | 1B | |||||
Cost of Goods Sold, Total | 206M | 318M | 333M | 372M | 377M | |||||
Gross Profit | 326M | 415M | 424M | 490M | 623M | |||||
Selling General & Admin Expenses, Total | 105M | 134M | 143M | 164M | 183M | |||||
R&D Expenses | 77.58M | 125M | 157M | 193M | 219M | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 34.7M | 76.06M | 82.79M | 94.59M | 92.76M | |||||
Other Operating Expenses, Total | 217M | 335M | 383M | 452M | 495M | |||||
Operating Income | 109M | 80M | 40.57M | 37.65M | 128M | |||||
Interest Expense, Total | -24.77M | -34.88M | -36.57M | -48.42M | -55.46M | |||||
Interest And Investment Income | 5.9M | 1.04M | 1.5M | 1.76M | 12.14M | |||||
Net Interest Expenses | -18.87M | -33.84M | -35.07M | -46.66M | -43.32M | |||||
Other Non Operating Income (Expenses) | -1.93M | -1.72M | 1.71M | -439K | 658K | |||||
EBT, Excl. Unusual Items | 88.32M | 44.45M | 7.2M | -9.45M | 85.48M | |||||
Merger & Related Restructuring Charges | -72.92M | -47.11M | -75.64M | -28.65M | -10.44M | |||||
Gain (Loss) On Sale Of Investments | 27.76M | - | 1.69M | - | - | |||||
Gain (Loss) On Sale Of Assets | - | - | - | - | - | |||||
Legal Settlements | - | 6.8M | - | - | - | |||||
EBT, Incl. Unusual Items | 43.16M | 4.14M | -66.74M | -38.1M | 75.04M | |||||
Income Tax Expense | 3.49M | -4.69M | -22.45M | -11.95M | 19.33M | |||||
Earnings From Continuing Operations | 39.66M | 8.83M | -44.29M | -26.14M | 55.71M | |||||
Net Income to Company | 39.66M | 8.83M | -44.29M | -26.14M | 55.71M | |||||
Net Income - (IS) | 39.66M | 8.83M | -44.29M | -26.14M | 55.71M | |||||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||||
Net Income to Common Incl Extra Items | 39.66M | 8.83M | -44.29M | -26.14M | 55.71M | |||||
Net Income to Common Excl. Extra Items | 39.66M | 8.83M | -44.29M | -26.14M | 55.71M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 0.59 | 0.12 | -0.53 | -0.31 | 0.65 | |||||
Basic EPS - Continuing Operations | 0.59 | 0.12 | -0.53 | -0.31 | 0.65 | |||||
Basic Weighted Average Shares Outstanding | 67.03M | 74.24M | 83.13M | 84.44M | 85.56M | |||||
Net EPS - Diluted | 0.58 | 0.12 | -0.53 | -0.31 | 0.64 | |||||
Diluted EPS - Continuing Operations | 0.58 | 0.12 | -0.53 | -0.31 | 0.64 | |||||
Diluted Weighted Average Shares Outstanding | 68.45M | 75.68M | 83.13M | 84.44M | 86.96M | |||||
Normalized Basic EPS | 0.82 | 0.37 | 0.05 | -0.07 | 0.62 | |||||
Normalized Diluted EPS | 0.81 | 0.37 | 0.05 | -0.07 | 0.61 | |||||
Payout Ratio | - | - | - | - | - | |||||
Supplemental Items | ||||||||||
EBITDA | 164M | 196M | 178M | 199M | 281M | |||||
EBITA | 156M | 180M | 163M | 187M | 272M | |||||
EBIT | 109M | 80M | 40.57M | 37.65M | 128M | |||||
EBITDAR | 173M | 210M | 191M | 208M | 288M | |||||
Total Revenues (As Reported) | 532M | 734M | 757M | 862M | 1B | |||||
Effective Tax Rate - (Ratio) | 8.09 | -113.38 | 33.64 | 31.38 | 25.76 | |||||
Current Domestic Taxes | -174K | 439K | 867K | 5.23M | 33.32M | |||||
Total Current Taxes | -174K | 439K | 867K | 5.23M | 33.32M | |||||
Deferred Domestic Taxes | 3.66M | -5.13M | -23.32M | -17.18M | -14M | |||||
Total Deferred Taxes | 3.66M | -5.13M | -23.32M | -17.18M | -14M | |||||
Normalized Net Income | 55.2M | 27.78M | 4.5M | -5.9M | 53.42M | |||||
Interest on Long-Term Debt | 24.77M | 34.88M | 36.57M | 48.42M | 55.46M | |||||
Supplemental Operating Expense Items | ||||||||||
Selling and Marketing Expenses | 43.95M | 49.96M | 58.6M | 68.85M | 79.27M | |||||
General and Administrative Expenses | 60.56M | 84.49M | 84.38M | 95.63M | 104M | |||||
Research And Development Expense From Footnotes | 77.58M | 125M | 157M | 193M | 219M | |||||
Net Rental Expense, Total | 8.31M | 14.27M | 12.93M | 9.18M | 6.76M | |||||
Imputed Operating Lease Interest Expense | - | 3.35M | 3.63M | 3.55M | 3.11M | |||||
Imputed Operating Lease Depreciation | - | 10.92M | 9.3M | 5.63M | 3.65M | |||||
Stock-Based Comp., COGS (Total) | 4.79M | 8M | 11.26M | 14.43M | 16.46M | |||||
Stock-Based Comp., R&D Exp. (Total) | 7.65M | 10.77M | 13.13M | 13.83M | 20.89M | |||||
Stock-Based Comp., S&M Exp. (Total) | 4.69M | 6.99M | 7M | 9.82M | 13.18M | |||||
Stock-Based Comp., G&A Exp. (Total) | 12.97M | 17.11M | 21.36M | 24.54M | 26.62M | |||||
Stock-Based Comp., Other (Total) | 15.32M | - | 342K | - | - | |||||
Total Stock-Based Compensation | 45.42M | 42.86M | 53.09M | 62.61M | 77.15M |